Logo Medical XPRT
Companies
Products
Services
Software
Training
Applications
Sign in
List your business
SYnAbs S.A.
About
  2. Companies
  3. SYnAbs S.A.
  4. Products
  5. Model C3aR - GPCR - Therapeutic ...

Model C3aR - GPCR - Therapeutic Blocking Anaphylatoxin Receptor - Antibodies

SHARE

hC3aR expression on the immunocompetent rat cell line. In black: non transfected rat cell line with a mean fluorescence of 4400. In red: stably transfected rat cell line with a mean fluorescence of 563000. Labelling: anti hC3ar Biolegend + GAM AF488.

Most popular related searches
monoclonal antibody
primary antibody
therapeutic antibody
Affinity comparison between BioLegend anti-C3aR and SYnAbs LO-C3aR on U2O
  • In blue: SynAbs anti-C3aR antibody
  • In red: BioLegend anti-C3aR antibody
  • Labelling: Biolegend or SynC3aR+ GAM AF647
Blocking capacity of SynC3aR on C3a binding on
  • In blue: C3a AF647 50 ng/ml with mean fluorescence 66000
  • In red: C3a AF647 50 ng/ml  + Synabs C3aR 833 ng/ml with mean Fluorescence 8800
  • In green: CCL1 AF647 50 ng/ml with mean fluorescence 1800
Inhibition curve of C3a-AF647 at various concentrations binding on USO2-C3aR
  • Maximum mean fluorescence (without SynC3aR) was 66000.
  • The maximal inhibition is reached, mean fluorescence 8800 at [SynC3aR]= 833 ng/ml,
  • The minimal labelling ( i.e; with CCL1-AF487) is at mean fluorescence = 1800.
  • At [SynC3aR]= 833 ng/ml, the inhibition rate is 89%